People with localized prostate cancer treated according to guidelines developed by an international panel of doctors are more likely to die of something other than the disease, new research shows. A ...

ArteraAI Prostate is now an FDA-regulated software (as a medical device) to estimate long-term outcomes and predict the benefit of hormone therapy for individual patients with localized prostate ...

Investigators trialed injection of an immune-stimulating substance (poly-ICLC) into the prostate gland using MRI-ultrasound fusion technology in patients scheduled to undergo radical prostatectomy.

NEEDHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help ...

PRESCIENTai, an AI-based digital histopathological image signature for risk of late distant recurrence and extended endocrine therapy (EET) benefit in hormone receptor–positive breast cancer. Use of a ...

Study results are based on Surveillance, Epidemiology, and End Results-Medicare data for 166,581 patients receiving surgery or radiation for localized prostate cancer.

New research in JNCCN—Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate cancer later in life, and treated according to NCCN ...

Among patients with grade group 1 prostate cancer, those belonging to higher risk groups were more likely to have adverse pathology and die from their disease. About 1 in 6 patients with grade group 1 ...

Long-term results from a phase 3 study showed that adding a focal boost to standard external beam radiotherapy (EBRT) improved 10-year biochemical disease-free survival (DFS) and reduced biochemical ...

SAN FRANCISCO -- Prophylactic whole-pelvic radiation therapy (RT) did not perform as expected for patients with unfavorable intermediate-risk or favorable high-risk prostate cancer, according to ...